Cargando…
Monotherapy in patients with pulmonary arterial hypertension at four German PH centres
BACKGROUND: Although combination therapy is the gold standard for patients with pulmonary arterial hypertension (PAH), some of these patients are still being treated with monotherapy. METHODS: We conducted a retrospective analysis at four German PH centres to describe the prevalence and characterist...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8061059/ https://www.ncbi.nlm.nih.gov/pubmed/33882879 http://dx.doi.org/10.1186/s12890-021-01499-2 |
_version_ | 1783681488996270080 |
---|---|
author | Stubbe, Beate Seyfarth, Hans-Jürgen Kleymann, Janina Halank, Michael Al Ghorani, Hussam Obst, Anne Desole, Susanna Ewert, Ralf Opitz, Christian F. |
author_facet | Stubbe, Beate Seyfarth, Hans-Jürgen Kleymann, Janina Halank, Michael Al Ghorani, Hussam Obst, Anne Desole, Susanna Ewert, Ralf Opitz, Christian F. |
author_sort | Stubbe, Beate |
collection | PubMed |
description | BACKGROUND: Although combination therapy is the gold standard for patients with pulmonary arterial hypertension (PAH), some of these patients are still being treated with monotherapy. METHODS: We conducted a retrospective analysis at four German PH centres to describe the prevalence and characteristics of patients receiving monotherapy. RESULTS: We identified 131 incident PAH patients, with a mean age of 64 ± 13.8 years and a varying prevalence of comorbidities, cardiovascular risk factors and targeted therapy. As in other studies, the extent of prescribed PAH therapy varied with age and coexisting diseases, and younger, so-called “typical” PAH patients were more commonly treated early with combination therapy (48% at 4–8 months). In contrast, patients with multiple comorbidities or cardiovascular risk factors were more often treated with monotherapy (69% at 4–8 months). Survival at 12 months was not significantly associated with the number of PAH drugs used (single, dual, triple therapy) and was not different between “atypical” and “typical” PAH patients (89% vs. 85%). CONCLUSION: Although “atypical” PAH patients with comorbidities or a more advanced age are less aggressively treated with respect to combination therapy, the outcome of monotherapy in these patients appears to be comparable to that of dual or triple therapy in “typical” PAH patients. |
format | Online Article Text |
id | pubmed-8061059 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-80610592021-04-22 Monotherapy in patients with pulmonary arterial hypertension at four German PH centres Stubbe, Beate Seyfarth, Hans-Jürgen Kleymann, Janina Halank, Michael Al Ghorani, Hussam Obst, Anne Desole, Susanna Ewert, Ralf Opitz, Christian F. BMC Pulm Med Research Article BACKGROUND: Although combination therapy is the gold standard for patients with pulmonary arterial hypertension (PAH), some of these patients are still being treated with monotherapy. METHODS: We conducted a retrospective analysis at four German PH centres to describe the prevalence and characteristics of patients receiving monotherapy. RESULTS: We identified 131 incident PAH patients, with a mean age of 64 ± 13.8 years and a varying prevalence of comorbidities, cardiovascular risk factors and targeted therapy. As in other studies, the extent of prescribed PAH therapy varied with age and coexisting diseases, and younger, so-called “typical” PAH patients were more commonly treated early with combination therapy (48% at 4–8 months). In contrast, patients with multiple comorbidities or cardiovascular risk factors were more often treated with monotherapy (69% at 4–8 months). Survival at 12 months was not significantly associated with the number of PAH drugs used (single, dual, triple therapy) and was not different between “atypical” and “typical” PAH patients (89% vs. 85%). CONCLUSION: Although “atypical” PAH patients with comorbidities or a more advanced age are less aggressively treated with respect to combination therapy, the outcome of monotherapy in these patients appears to be comparable to that of dual or triple therapy in “typical” PAH patients. BioMed Central 2021-04-21 /pmc/articles/PMC8061059/ /pubmed/33882879 http://dx.doi.org/10.1186/s12890-021-01499-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Stubbe, Beate Seyfarth, Hans-Jürgen Kleymann, Janina Halank, Michael Al Ghorani, Hussam Obst, Anne Desole, Susanna Ewert, Ralf Opitz, Christian F. Monotherapy in patients with pulmonary arterial hypertension at four German PH centres |
title | Monotherapy in patients with pulmonary arterial hypertension at four German PH centres |
title_full | Monotherapy in patients with pulmonary arterial hypertension at four German PH centres |
title_fullStr | Monotherapy in patients with pulmonary arterial hypertension at four German PH centres |
title_full_unstemmed | Monotherapy in patients with pulmonary arterial hypertension at four German PH centres |
title_short | Monotherapy in patients with pulmonary arterial hypertension at four German PH centres |
title_sort | monotherapy in patients with pulmonary arterial hypertension at four german ph centres |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8061059/ https://www.ncbi.nlm.nih.gov/pubmed/33882879 http://dx.doi.org/10.1186/s12890-021-01499-2 |
work_keys_str_mv | AT stubbebeate monotherapyinpatientswithpulmonaryarterialhypertensionatfourgermanphcentres AT seyfarthhansjurgen monotherapyinpatientswithpulmonaryarterialhypertensionatfourgermanphcentres AT kleymannjanina monotherapyinpatientswithpulmonaryarterialhypertensionatfourgermanphcentres AT halankmichael monotherapyinpatientswithpulmonaryarterialhypertensionatfourgermanphcentres AT alghoranihussam monotherapyinpatientswithpulmonaryarterialhypertensionatfourgermanphcentres AT obstanne monotherapyinpatientswithpulmonaryarterialhypertensionatfourgermanphcentres AT desolesusanna monotherapyinpatientswithpulmonaryarterialhypertensionatfourgermanphcentres AT ewertralf monotherapyinpatientswithpulmonaryarterialhypertensionatfourgermanphcentres AT opitzchristianf monotherapyinpatientswithpulmonaryarterialhypertensionatfourgermanphcentres |